Engage MSI From evidence to
decision advantage.
MSI connects ten research domains, three flagship programmes and a disciplined publication model so that medicines-security evidence can be found, tested, cited and applied.
One research system. Clear routes to every output.
MSI follows an open-access-first approach. Published public research is readable, citable, downloadable and shareable. Only clearly identified commissioned intelligence may use approved partner access.
Research papers
Open, permanent and citable studies that define medicines security as a strategic field.
Browse publicationsPolicy briefs
Concise evidence-to-action formats designed for public and institutional decision-makers.
View output registerIndices & dashboards
Transparent frameworks for measuring capability, dependency, exposure and resilience.
Explore the IndexCountry assessments
National and regional profiles that connect domestic capability to global systems.
See the programmeStrategic outlooks
Forward intelligence on shocks, technology, industrial change and policy choices.
Explore MSI-SISPartner intelligence
Carefully governed commissioned work for approved institutional partners.
Understand accessEight priorities shaping MSI’s research agenda.
The ten domains describe the medicines-security system. These eight themes define the principal questions through which MSI develops research, intelligence, partnerships and policy impact.
Medicines Security
The institutions, capabilities and international relationships required to protect the continuous, equitable and trusted availability of essential medicines.
Pharmaceutical Geopolitics
How strategic competition, trade, alliances, conflict and state power reshape pharmaceutical dependencies and access.
AI for Medicines Security
Responsible use of artificial intelligence to improve foresight, visibility, preparedness and decision quality across medicines systems.
Pharmaceutical Industrial Strategy
Public and private choices that build viable discovery, manufacturing, regulatory, workforce and innovation capability.
Pharmaceutical Supply Chain Resilience
The visibility, redundancy, adaptability and coordination needed to withstand disruption across multi-tier pharmaceutical networks.
Strategic Health Security
Medicines capability as a component of national preparedness, societal resilience and response to high-consequence health threats.
Life Sciences Investment
How capital allocation, incentives and ownership structures shape long-term pharmaceutical capability and public value.
Pharmaceutical Governance
The authority, accountability and institutional design required to govern complex pharmaceutical risks in the public interest.
Ten domains.
One security system.
Each domain has a defined mandate, priority scope and core questions. Together they connect the scientific, industrial, institutional and geopolitical conditions that determine medicines security.
Research designed to produce institutional capability.
The flagship portfolio turns the MSI framework into defined programmes, workstreams and outputs. Each programme page states what exists, what is planned and how institutions may participate.
Strategic Intelligence System
A decision architecture connecting evidence, indicators, scenarios and response options across all ten domains.
Medicines Security Index
A comparative framework for assessing national capability, exposure and resilience.
Medicines Security Papers
A foundational series defining the discipline, its evidence base and implications for public leadership.
Published, developing and proposed work—clearly distinguished.
MSI Strategic Papers 01–04
Four open-access foundational papers with permanent pages, citations, sharing and PDF downloads.
In developmentMedicines Security Index methodology
Indicator architecture, evidence protocol and independent technical-review model.
Programme stageStrategic Intelligence System
A proposed decision architecture for indicators, scenarios, dashboards and executive briefs.
Open for collaborationCountry and institutional assessments
Evidence-led baseline studies developed with authorised public, research and institutional partners.
Contribute evidence, methods or institutional capability.
MSI welcomes serious proposals from scholars, governments, research institutes and mission-aligned organisations.